Compugen Ltd CGEN Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$1.96 up $0.04, 2.08% at close Nov 6
Last close · Previous close $1.92
- Market cap
- $185.33MAt the Nov 6 close
- P/E ratio
- 5.30On last 12 months’ EPS
- Diluted EPS
- $0.37Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$1.96up $0.04, 2.08%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$1.92Nov 5
- Volume183.99KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume235.85KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $1.43 to $3.24; now $1.96
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
CGEN beat the S&P 500 in 3 of 7 periods.
| Period | CGEN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CGEN: down 11.7% S&P 500: down 5.6% | CGEN trailed the S&P 500 by 6.1 percentage points Trailed |
| 3M | CGEN: down 14.8% S&P 500: down 4.1% | CGEN trailed the S&P 500 by 10.7 percentage points Trailed |
| YTD | CGEN: up 28.1% S&P 500: up 8.7% | CGEN beat the S&P 500 by 19.4 percentage points Beat |
| 1Y | CGEN: up 19.5% S&P 500: up 10.9% | CGEN beat the S&P 500 by 8.6 percentage points Beat |
| Long term | ||
| 3Y | CGEN: up 170.6% S&P 500: up 75.0% +39.4% vs +20.5% a year | CGEN beat the S&P 500 by 95.6 percentage points Beat |
| 5Y | CGEN: down 70.8% S&P 500: up 67.8% −21.8% vs +10.9% a year | CGEN trailed the S&P 500 by 138.6 percentage points Trailed |
| 10Y | CGEN: down 67.1% S&P 500: up 313.1% −10.5% vs +15.2% a year | CGEN trailed the S&P 500 by 380.2 percentage points Trailed |
$10,000 invested in CGEN 10 years ago (Nov 4, 2016) would be worth about $3,294 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
CGEN beat the S&P 500 in 3 of 7 periods.
| Period | CGEN and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CGEN: down 11.7% S&P 500: down 5.6% | CGEN trailed the S&P 500 by 6.1 percentage points Trailed |
| 3M | CGEN: down 14.8% S&P 500: down 4.3% | CGEN trailed the S&P 500 by 10.5 percentage points Trailed |
| YTD | CGEN: up 28.1% S&P 500: up 7.8% | CGEN beat the S&P 500 by 20.3 percentage points Beat |
| 1Y | CGEN: up 19.5% S&P 500: up 9.7% | CGEN beat the S&P 500 by 9.8 percentage points Beat |
| Long term | ||
| 3Y | CGEN: up 170.6% S&P 500: up 68.8% +39.4% vs +19.1% a year | CGEN beat the S&P 500 by 101.8 percentage points Beat |
| 5Y | CGEN: down 70.8% S&P 500: up 56.9% −21.8% vs +9.4% a year | CGEN trailed the S&P 500 by 127.7 percentage points Trailed |
| 10Y | CGEN: down 67.1% S&P 500: up 252.6% −10.5% vs +13.4% a year | CGEN trailed the S&P 500 by 319.7 percentage points Trailed |
$10,000 invested in CGEN 10 years ago (Nov 4, 2016) would be worth about $3,294 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$19.45
Closing high on . Now 89.9% below that record.
Split-adjusted daily closes since Aug 11, 2000.
Stock splits
CGEN hasn’t split since its price history begins in 2000.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
5.3×The Nov 6 close ÷ diluted EPS over the last 12 months ($0.37)
The range covers daily P/E ratios from Oct 28, 2021 to Nov 6, 2026, each based on the previous 12 months of earnings.
CGEN trades at 5.3× its earnings over the last 12 months, below its 5-year median of 6.4×. In plain terms, buyers are paying about $5 for each $1 of profit from the past year. How to read P/E
Other valuation measures
- 2.5×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 2.1×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - $63.05MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own CGEN DCF in Excel. Value Compugen with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $74.00Mup 234.2%
- Net income
- $35.19M
- Diluted EPS
- $0.37
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $17.13M | $1.28M | $0.01 |
| Q4 FY24 (Dec 31, 2024) | $1.47M | −$6.12M | −$0.07 |
| Q1 FY25 (Mar 31, 2025) | $2.28M | −$7.18M | −$0.08 |
| Q2 FY25 (Jun 30, 2025) | $1.26M | −$7.34M | −$0.08 |
| Q3 FY25 (Sep 30, 2025) | $1.89M | −$6.98M | −$0.07 |
| Q4 FY25 (Dec 31, 2025) | $67.33M | $56.85M | $0.60 |
| Q1 FY26 (Mar 31, 2026) | $2.18M | −$7.67M | −$0.08 |
| Q2 FY26 (Jun 30, 2026) | $2.60M | −$7.01M | −$0.08 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $6.00M | −$34.20M | −$0.41 |
| FY22 (Dec 31, 2022) | $7.50M | −$33.69M | −$0.39 |
| FY23 (Dec 31, 2023) | $33.46M | −$18.75M | −$0.21 |
| FY24 (Dec 31, 2024) | $27.86M | −$14.23M | −$0.16 |
| FY25 (Dec 31, 2025) | $72.76M | $35.34M | $0.38 |
Margins
- Gross 86.9%
- Operating 40.9%
- Net 47.6%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- Not reportedLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flowNot reportedLast 12 months
- Capital spendingNot reportedLast 12 months
Shareholder returns
- Not reportedLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paidNot reportedLast 12 months
Balance sheet
- $129.83MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$3.02MAs of Jun 30, 2026
- Net cash$126.81MAs of Jun 30, 2026
- 5.72As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.03As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 42.6%Last 12 months
Over the last 12 months, Compugen’s net income was 42.6% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 26.1%Last 12 months
Over the last 12 months, Compugen’s net income was 26.1% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Compugen Ltd
Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI-powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of COM701, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, is currently being evaluated in a blinded randomized ovarian cancer adaptive platform trial as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902, Compugen's anti-TIGIT antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, Compugen has an early-stage immuno-oncology pipeline that consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Israel
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
CGEN news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
CGEN stock FAQ
What is CGEN stock’s price today?
Compugen (CGEN) traded at $1.96 at the close on , up $0.04 (2.08%) from the previous close of $1.92. Over the past 52 weeks it has traded between $1.43 and $3.24.
If you invested $1,000 in CGEN 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in CGEN on would be worth about $329 at the close on , a total return of −67.1%. The same $1,000 would be worth $292 if invested five years ago, $1,195 if invested one year ago, and $681 if invested 20 years ago. Past performance doesn’t predict future returns.
What is Compugen’s market cap?
Compugen’s market capitalization is about $185.3 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $1.96 (how market cap works). Compugen reported 94.56M shares outstanding at the end of its latest quarter ().
What is CGEN’s P/E ratio?
CGEN trades at 5.3 times its diluted earnings over the four quarters to ($0.37 per share), at the close. Over the past five years its P/E has ranged from 4.0 to 108.1, with a median of 6.4. (How the P/E ratio works.)
How much revenue does Compugen make?
Compugen reported $74.0 million of revenue over the four quarters to , up 234.2% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $2.6 million, up 107.0% from a year earlier.
Is Compugen profitable?
Yes. Compugen earned $35.2 million of net income over the four quarters to , a net margin of 47.6%, and its operating margin was 40.9% (what margins tell you).
What are CGEN’s earnings per share?
CGEN’s diluted earnings per share were $0.37 over the four quarters to , compared with −$0.22 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.08 per share, against −$0.08 a year earlier (how EPS works).
Does CGEN pay a dividend?
Compugen hasn’t paid a dividend in the last twelve months.
What is CGEN’s 52-week high and low?
Over the past 52 weeks CGEN has traded as low as $1.43 and as high as $3.24. At $1.96 at the close on , it is 39.4% below that high and 37.1% above the low.
What is CGEN’s all-time high?
CGEN’s highest closing price was $19.45 on , adjusted for stock splits. At $1.96 at the close on , it is 89.9% below that record.
Has CGEN stock ever split?
No. CGEN hasn’t split since its price history begins in 2000.
How has CGEN stock performed?
Including dividends and measured to the close on , CGEN has returned +28.1% so far this year and +19.5% over the past year, and −70.8% over five years (−21.8% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Compugen in?
Compugen is in the Healthcare sector and the Biotechnology industry, and is headquartered in Israel.
What exchange does CGEN trade on?
Compugen trades on the Nasdaq under the ticker symbol CGEN. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.